Related Experiment Video
Updated: Aug 7, 2026
04:36
Noninvasive Electrocardiography in the Perinatal Mouse
Published on: June 12, 2020
The Use of Cardiotonic Drugs in Neonates
Iyshwarya Stapleton1, Eugene Dempsey1
1INFANT Research Centre, University College Cork, Cork, Ireland; Department of Paediatrics and Child Health, University College Cork, Cork, Ireland.
Clinics in Perinatology
|August 5, 2026
Summary
Vasoactive agents are common in neonatal intensive care units (NICU), but evidence for their use is limited. More research is needed to understand dosing, safety, and long-term effects in neonates.
Area of Science:
- Neonatal pharmacology
- Pediatric critical care medicine
- Cardiovascular pharmacology
Background:
- Vasoactive agents are frequently used in neonatal intensive care units (NICU).
- Evidence-based guidelines for their use in neonates are lacking due to insufficient clinical trials.
- Challenges exist in developing age-appropriate cardiotonic formulations for this population.
Purpose of the Study:
- To summarize commonly used vasoactive agents in the NICU.
- To review clinical scenarios where these agents are applied.
- To highlight the need for improved evidence regarding their use in neonates.
Main Methods:
- This study is an overview of existing literature and clinical practices.
- It synthesizes information on vasoactive agent usage in neonatal intensive care.
Main Results:
- Vasoactive agents are widely used in NICU settings.
- Current administration lacks robust evidence for optimal dosing, safety, and efficacy.
- A significant gap exists in age-appropriate cardiotonic formulations.
Conclusions:
- There is a critical need for well-designed clinical trials in neonates.
- Future research should focus on evidence-based dosing, safety, and long-term outcomes.
- Incorporating objective monitoring tools like echocardiography is essential for future trials.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...